title: Individualized chemotherapeutic regimen for each histological subtype of ovarian carcinoma.
abstract: Ovarian carcinoma can be classified into the following distinct two groups in terms of chemosensitivity. The chemosensitive group includes serous, endometrioid, transitional cell carcinoma (TCC), and undifferentiated carcinoma, with a response rate to CDDP-based chemotherapy (CTX) being approximately 80 to 90%. Even within this chemosensitive group, the mode of the response to chemotherapy may vary by the histologic subtype or the grade of differentiation. The chemo-resistant group consists of mucinous and clear-cell adenocarcinoma (CCA), with a response rate to CDDP-based regimen being less than 5% or none. Especially, for pure CCA of the ovary, no one case has ever been reported to have shown an appreciable response to a CDDP-based regimen. As a result, advanced patients with mucinous carcinoma or CCA of the ovary not amenable to a complete surgery have a poor prognosis. The author developed a promising new regimen consisting of CPT-11 with mitomycin-C based both on in vitro and in vivo chemosensitivity tests. Thus, an individualized regimen may be required for both CDDP-sensitive and resistant diseases.
authors.affiliation: Department of Gynecology, Cancer Institute Hospital, Tokyo, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Shimizu
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D002277:Carcinoma / Q000188:drug therapy; D018269:Carcinoma, Endometrioid / Q000188:drug therapy; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy; D002945:Cisplatin / Q000008:administration & dosage; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D000077146:Irinotecan; D016685:Mitomycin / Q000008:administration & dosage; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology*
chemical_list: D016685:Mitomycin; D000077146:Irinotecan; D002945:Cisplatin; D002166:Camptothecin